FindTrial
Sign In

Effect of moderate-intensity interval training combined with external counterpulsation therapy on cardiac function in patients with heart failure with reduced ejection fraction

Effect of moderate-intensity interval training combined with external counterpulsation therapy on cardiac function in patients with heart failure with reduced ejection fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112720
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-11-20
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Experimental group:Standardized health education + moderate-intensity interval training + enhanced external counterpulsation therapy
Control group:Standardized health education

Sponsors

The First Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Fulfill the diagnostic criteria for chronic heart failure as specified in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024; (2) Left ventricular ejection fraction (LVEF) <= 50%; (3) New York Heart Association (NYHA) functional class II–III; (4) Age between 18 and 75 years. (5) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Left ventricular ejection fraction (LVEF) > 50%, or patients diagnosed with diastolic heart failure; (2) Cardiovascular contraindications: aortic diseases (e.g., aortic aneurysm, dissection, severe aortic regurgitation), hemodynamically unstable valvular heart disease or congenital heart disease, severe pulmonary hypertension (mean pulmonary artery pressure > 50 mmHg), etc.; (3) Bleeding and thrombotic risks: bleeding tendency or ongoing anticoagulant therapy (INR > 2.0), lower extremity venous thrombosis, active phlebitis, or deep vein thrombosis; (4) Malignant tumor, severe hepatic or renal dysfunction; (5) Severe neurological, muscular, or osteoarticular disorders affecting exercise capacity, or abnormal muscle strength; (6) Cognitive impairment disorders: including epilepsy, Alzheimer’s disease, severe vascular dementia or other forms of dementia, history of cerebral infarction with residual impairment, dementia, etc.

Design outcomes

Primary

MeasureTime frame
Ventricular remodeling indicators;Non-invasive hemodynamic indicators;Cardiac autonomic function indicators ;Cardiopulmonary exercise test;6-minute walk trial;SF-36 Quality of Life Scale;Minnesota Living with Heart Failure Questionnaire;—

Secondary

MeasureTime frame
Pulmonary function tests;Cardiovascular disease risk factors;—

Countries

China

Contacts

Public ContactWang Cuihua

The First Hospital of Hebei Medical University

58303056@hebmu.edu.cn+86 150 8117 0568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026